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ences on a scale running from 1 (perfect health) to 0 (all
worst or death depending on the interviewee’s decision).
The 8 single-attribute value functions were directly re-
vealed as well as the corner states values. Rating of par-
ticular multi-attribute health states was also done using
both VAS and SG. RESULTS: The limited number of
questionnaires excluded at the various different stages of
building the multiattribute utility function demonstrated
that such approaches are viable manners of gathering
original and high-quality information on the values and
judgements held by individuals in France with regard to
health. Secondly, analysis concluded that collected data
permit 1) to fit multi-attribute value and utility functions
for many individuals and 2) to discuss the appropriate-
ness of the multiplicative functional form. Results ob-
tained at the person-mean and person-median levels from
the French survey will be presented and discussed. Our
results confirm the interindividual variability of the pref-
erences already reported among Anglo-Saxon popula-
tions. As for most of the latter, these variations cannot be
explained by standard socio-demographic characteristics
such as the age, sex or socio-economic level of the inter-
viewees.
PMDP4
THE INFLUENCE OF NON-COMPLIANCE ON 
THE EFFECTIVENESS AND COST-
EFFECTIVENESS OF DRUG THERAPIES
Hughes D, Bagust A, Haycox A, Walley T
Prescribing Research Group, Department of Pharmacology & 
Therapeutics, University of Liverpool, Liverpool, UK
OBJECTIVES: To develop a model for predicting thera-
peutic effectiveness from efficacy data. To estimate the
resource and health implications of sub-optimal drug use
in the general population. METHODS: A stochastic model-
ling approach was adopted to simulate drug effect ac-
cording to time. Non-compliance was simulated by prob-
ability functions describing the three main forms of drug-
taking behaviour: timing errors, missed doses and drug
holidays. Standard pharmacokinetic (PK) simulations for
multiple oral dosing based on these dosing profiles pro-
vided a basis for pharmacodynamic (PD) modelling in or-
der to evaluate the time course of drug effect. Iterations
were made for each PK-PD model with random compli-
ance profiles. RESULTS: Although the consequences of
non-compliance are varied, and mainly dependent upon
the disease being treated, some drugs are more forgiving
to non-compliance than others. That is, in the presence of
erratic dosing behaviour, therapeutic effect may be main-
tained. Forgiveness is an attribute which is dependent
both upon the properties of the drug and the pathophysi-
ology of the disease. The model demonstrates that drugs
which have a long duration of action in relation to their
dosing interval are the most forgiving, and this may be pre-
dicted on the basis of their PK-PD characteristics. CON-
CLUSIONS: Non-compliance is an important factor of
drug effectiveness. The forgiveness of a drug determines
the extent to which efficacy is affected by sub-optimal
drug use and has implications when considering cost-
effectiveness.
MULTIPLE DISORDERS—METHODOLOGY ISSUES
PMDM1
POWER AND SAMPLE SIZE CALCULATIONS 
FOR A CLINICAL TRIAL CONSIDERING COST-
EFFECTIVENESS AND STATISTICAL ERRORS
Kamae I, Yanagisawa S
Division of Health Informatics and Sciences, Graduate School 
of Medicine, Kobe University, Kobe, Japan
In the last meeting of ISPOR, we presented a paper that
showed the actual cost-effectiveness of treatments in
practice can be reduced by the influence of statistical er-
rors such as type II () and type III (). OBJECTIVE:
Based on that research, this paper developed a further
theoretical framework for such estimation which pro-
vides a new method for power analysis of a clinical trial
and proper translation of its outcomes in terms of cost-
effectiveness. METHODS: Consider a statistical model of
a clinical trial for two regimens: a new treatment TA and
TB. Under the traditional two-sample binomial analysis,
we theoretically expanded it into power and sample sized
calculations with the cost-effectiveness ratios A and B,
respectively, for the regimens TA and TB. Furthermore, we
assume that the truth is TA is more cost-effective than TB.
Then, the binomial analyses were generalized under the
decision-analytic model that can reflect a reality in prac-
tice with three alternatives according to no error,  and 
errors possibly contained in the statistical conclusion of
the clinical trials for TA and TB. RESULTS: Two formu-
lae were developed mathematically to incorporate cost-
effectiveness; one is an expansion of the traditional
formula for sample-size calculation with the cost-effec-
tiveness ratios A and B, and the other a more realistic
one with A and B, and the modified cost-effectiveness
ratio adjusted by the statistical  and  errors using A
and B. CONCLUSIONS: The newly developed formulae
can offer a more theoretically sound description to design
a clinical trial beyond the traditional techniques.
PMDM2
GUIDING PRINCIPLES TO COMPARE THE 
EFFICACY OF NOVEL DRUGS USING RCT 
MATCHED ARM COMPARISONS
Läer C, LeLorier J
Centre de recherche, Hôtel-Dieu du Centre hospitalier de 
l’Université de Montréal, Montréal, QC, Canada
OBJECTIVE: Our goal was to develop a set of evidence-
based guiding principles for the comparison of two novel
drugs of the same therapeutic class when direct head-to-
head comparisons are lacking. The principles are in-
tended to guide researchers, decision-makers, and formu-
374 Abstracts
lary committee members. METHOD: We addressed the
issue in two steps: First, we developed guiding principles
which should be evidence based, applicable, and credible,
and second, we proposed a method called randomized
clinical trial (RCT)—matched-arm comparison to estab-
lish therapeutic equivalence where the application of the
appropriate statistical tests, as well as the a priori defini-
tion of the clinical meaningfulness of the results is
stressed. RESULTS: The guiding principles stress the fol-
lowing domains with respect to study selection: The liter-
ature search, the definition and comparison of the popu-
lation parameters such as the pathologic condition,
inclusion and exclusion criteria, baseline characteristics,
placebo response, the drugs, the outcome, and issues such
as drug safety, potential of drug-drug interactions and
potential compliance issues. Once appropriate RCTs have
been identified and comparability is established, the pri-
mary endpoints of the two treatment arms of the two
RCTs are compared through statistical equivalence tests
using a priori defined meaningful differences for clinical end-
points. CONCLUSION: The application of the principles
and the RCT-matched-arm comparison should lead deci-
sion-makers to applicable valid decisions based on unbi-
ased results, with accurate, reproducible comparisons
and predictable clinical results.
PMDM3
PROJECTING ECONOMIC RESULTS OF A 
EUROPEAN TRIAL TO THE UNITED STATES: 
ISSUES AND METHODS
Sorensen S1, de Lissovoy G1, Mathur S1, Duttagupta S2
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Outcomes Research Group, Pfizer Inc., New York, NY, USA
OBJECTIVE: Many pivotal clinical trials include an eco-
nomic component. Because of cost and logistic con-
straints, trials are rarely conducted in every nation where
the product will be marketed. For that reason economic
results obtained in one nation (“source”) are often pre-
sented to decision-makers in another nation (“target”).
Information may be seen as more relevant if findings
from the source nation are projected to the target nation.
Study objective was to identify sources of cross-national
variation in the cost of an episode of care, approaches to
adjust variation, and practical problems in trans-national
adaptation of economic clinical trials. RESULTS: We
present a case study based on analysis of economic end-
points from the Donepezil Nordic Family Impact Study.
Through literature review and experience, we identified
four potential components of transnational cost varia-
tion: 1) relative prices for services (i.e. primary care office
visit fee relative to price for chest X-ray), 2) quantity of
resources (i.e. length of stay for similar hospital admis-
sion), 3) inputs to health production (certain procedures/
services are performed in one nation but do not exist in
the other), and 4) patient population (case definition and
patient demographic characteristics). Approaches to ad-
dressing each source of variation include 1) substituting
unit prices of the target country, 2) adjusting observed re-
source quantity to typical treatment pattern of the target
country, 3) replacing selected treatment encounters with
functionally analogous service existing in target country,
and 4) sub-setting original trial cohort to obtain outcomes
in a patient population representative of the target country.
CONCLUSIONS: Adapting a pharmacoeconomic study is
a process of modifying empirical data. The sequence of ad-
justments represents a progressive trade-off between inter-
nal validity (reliance on empirical data) and external validity
(replication of the target country environment). Transpar-
ency enhances credibility of this process by demonstrating
the separate effect of each category of adjustment.
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MEASUREMENTS OF HEALTH STATUS
IN DENMARK
Wittrup-Jensen KU, Brooks R, Gudex C, Pedersen KM
Institute of Public Health, University of Southern Denmark, 
Odense, Denmark
OBJECTIVE: There are three main aims of this study. (1)
To create a profile of the state of health in the Danish
population.For this purpose we selected three multi-attrib-
ute classification systems: EQ-5D, SF-36 and 15D. The
selection of instruments was based, inter allia, on the
availability of validated Danish versions and on the in-
struments being used internationally. (2) To evaluate the
instruments in terms of their validity and reliability in
measuring a population’s health status. (3) To compare
the instruments in the measurement and evaluation of
health-related quality of life. METHODS: The study is
based on postal questionnaires, performed by a profes-
sional survey institute. A random sample of around 6.000
individuals of the Danish adult population was contacted
by phone, asking whether they would be interested in
completing the questionnaires. Around 5.000 agreed to
participate, and 3.400 responded (a response rate of
68%). The questionnaires contained all three instruments,
including the complete EQ-5D VAS scaling exercise. A
randomized experiment with 6 versions of EQ-5D con-
taining varied wording and response categories was also
embedded in the study. CONCLUSION: This study will
provide a rich data set, the analysis of which should be
an important contribution to the measurement and valu-
ation of health-related quality of life both in Denmark
and in the wider international context. 
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